← Back to Search
Role Of P-glycoprotein And Cytochrome P450 3A In Limiting Oral Absorption Of Peptides And Peptidomimetics.
V. Wacher, J. A. Silverman, Y Zhang, L. Benet
Published 1998 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
Cytochrome P450 3A4 (CYP3A4), the major phase I drug metabolizing enzyme in humans, and the MDR1 gene product P-glycoprotein (P-gp) are present at high concentrations in villus tip enterocytes of the small intestine and share a significant overlap in substrate specificity. A large body of research both in vitro and in vivo has established metabolism by intestinal CYP3A4 as a major determinant of the systemic bioavailability of orally administered drugs. More recently it has been recognized that drug extrusion by intestinal P-gp can both reduce drug absorption and modulate the effects of inhibitors and inducers of CYP3A-mediated metabolism. There is relatively little data regarding the effects of CYP3A and P-gp on peptide drugs; however, studies with the cyclic peptide immunosuppresant cyclosporine as well as peptidomimetics such as the HIV-protease inhibitor saquinavir (Invirase) and a new cysteine protease inhibitor K02 (Morpholine-Urea-Phe-Hphe-Vinyl sulfone; Axys Pharmaceuticals) provide some insight into the impact of these systems on the oral absorption of peptides.
This paper references
Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.
T. Aoyama (1989)
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
K. Thummel (1994)
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.
D. Nelson (1996)
Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.
F. Gonzalez (1988)
Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein.
J. Hunter (1991)
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.
E. Schuetz (1996)
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Y. Zhang (1998)
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.
M. Hansen (1989)
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
D. Kempf (1997)
Cytochrome P450 CYP3A5 in the human anterior pituitary gland
G. Murray (1995)
Regulation of human liver cytochromes P‐450 in family 3A in primary and continuous culture of human hepatocytes
E. Schuetz (1993)
Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
M. Hebert (1992)
Purification and properties of cytochrome P-450 from homogenates of human fetal livers.
M. Kitada (1985)
Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver.
J. Schuetz (1989)
Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.
P. Watkins (1987)
Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
Kenneth S. Lown (1997)
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
D. Gómez (1995)
Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family.
S. Wrighton (1989)
Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.
P. Borst (1993)
Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
A. Kim (1998)
Grapefruit juice and saquinavir.
J. Js (1995)
An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials
A. Parkinson (1996)
Bimodal distribution of renal cytochrome P450 3A activity in humans.
B. Haehner (1996)
Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
S. Wrighton (1990)
Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.
K. Kivistö (1996)
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
M. Paine (1997)
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
P. Schmiedlin-Ren (1997)
CYP3A gene expression in human gut epithelium.
J. Kolars (1994)
Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues.
R. McKinnon (1995)
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV‐infected patients
C. Merry (1997)
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
K. Lown (1997)
Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism
K. Thummel (1996)
Detection of human lung cytochromes P450 that are immunochemically related to cytochrome P450IIE1 and cytochrome P450IIIA.
C. Wheeler (1992)
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
Franz Thiebaut (1987)
Expression of a multidrug-resistance gene in human tumors and tissues.
A. Fojo (1987)
The effect of water‐soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers
T. Chang (1996)
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
E. Schuetz (1996)
Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation
G. Fricker (1996)
Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P 450.
T. Cresteil (1982)
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
J. Kolars (1992)
Expression and localization of CYP3A4 and CYP3A5 in human lung.
S. Anttila (1997)
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
J. van Asperen (1997)
Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.
C. Merry (1997)
Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins.
H. Hashimoto (1995)
Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
A. Schinkel (1995)
Selective expression of CYP3A5 and not CYP3A4 in human blood.
S. K. Janardan (1996)
Disposition of intravenous and oral cyclosporine after administration with grapefruit juice
M. Ducharme (1995)
Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.
T. Tateishi (1997)
Vinyl sulfones as mechanism-based cysteine protease inhibitors.
J. Palmer (1995)
The Fetal Specific GeneCYP3A7Is Inducible by Rifampicin in Adult Human Hepatocytes in Primary Culture
J. Greuet (1996)
Identification of a polymorphically expressed member of the human cytochrome P-450III family.
S. Wrighton (1989)
First-pass metabolism of cyclosporin by the gut
J. Kolars (1991)
The biochemistry of P-glycoprotein-mediated multidrug resistance.
J. A. Endicott (1989)
Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver.
D. T. Molowa (1986)
Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine.
A. Lampen (1996)
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
A. Sparreboom (1997)
Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control.
H. Hashimoto (1993)
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
V. Wacher (1995)
First‐pass metabolism of midazolam by the human intestine
M. Paine (1996)
Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes.
T. Kocarek (1995)
Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?
Y. Jounaïdi (1996)
Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver.
J. Schuetz (1994)
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
T. Shimada (1994)
Active secretion and enterocytic drug metabolism barriers to drug absorption 1 PII of original artic
V. Wacher (1996)
Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver.
J. Hakkola (1994)
Expression of cytochrome P450 3A in amphibian, rat, and human kidney.
E. Schuetz (1992)
Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues.
I. de Waziers (1990)
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
T. Mosmann (1983)
Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450.
M. Komori (1989)
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
K. Thummel (1994)
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
J. C. Gorski (1994)
The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450.
G. Murray (1988)
Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s.
D. Waxman (1991)
Biochemistry of multidrug resistance mediated by the multidrug transporter.
M. Gottesman (1993)
Identification of an inducible form of cytochrome P-450 in human liver.
P. Watkins (1985)
Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine
C. Wu (1995)
Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
M. E. Fitzsimmons (1997)
Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical.
K. Lown (1998)
Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
K. Lown (1994)
Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein.
M. Müller (1996)
Fetus-specific expression of a form of cytochrome P-450 in human livers.
M. Komori (1990)
Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations.
M. Kitada (1987)
This paper is referenced by
The intracellular pharmacology of antiretroviral protease inhibitors.
J. Ford (2004)
CYP3A4 and MDR Mediated Interactions in Drug Therapy
D. Pal (2006)
D09 P‐glycoprotein in the intestine, liver and kidney of the horse
E. Tydén (2006)
Glucocorticoid pharmacogenetics in Addison's disease - The role of the immunophilin FK506-binding protein (FKBP51) for glucocorticoid sensitivity
Martha Schei Hynne (2008)
Analysis of the molecular association of rifampicin with hydroxypropyl-β-cyclodextrin
D. A. Ferreira (2006)
Gender and pharmacokinetics
B. Modjtahedi (2012)
Amino acids in oral drug delivery:salts, ion-pairs and transcriptomics
Amr Elshaer (2013)
Impact of inflammation on the duodenal mRNA expression of CYP3A and P‐glycoprotein in children with Crohn's disease
M. Fakhoury (2006)
Increased Oral Bioavailability of Itraconazole and Its Active Metabolite, 7‐Hydroxyitraconazole, When Coadministered With a Vitamin C Beverage in Healthy Participants
S. H. Bae (2011)
Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver Transplantation
Ingjerd Sæves (2014)
I NTERACTIONS AMONG D RUGS FOR HIV AND O PPORTUNISTIC I NFECTIONS
C. P. Iscitelli (2001)
Effect of green tea extract on expression of proteins involved in drug transport and metabolism and on the expression and secretion of the chemokine interleukin-8 in intestinal cell lines
Philosophisch-Naturwissenschaftlichen Fakultät (2006)
Effects of Citrus Fruit Juices on P-glycoprotein-mediated Transport in L-MDR1 Cells and CYP3A4-mediated Metabolism in Human Intestinal Microsomes
Siok-Lam Lim (2008)
Transporters in the Gastrointestinal Tract
P. Anderle (2008)
INFLUENCE OF POMEGRANATE JUICE ON THE CYP3A4-MEDIATED METABOLISM AND P-GLYCOPROTEIN MEDIATED TRANSPORT OF SAQUINAVIR IN VIVO AND EX VIVO MODELS
Sridhar Vemulapalli (2016)
Antibiotic efflux pumps.
F. Van Bambeke (2000)
Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
X. Cao (2005)
Novel HIV-1 capsid-targeting small molecules of the PF74 binding site.
L. Wang (2020)
Microfluidic gut-on-a-chip with three-dimensional villi structure
Kyu-Young Shim (2017)
Two‐ to three‐fold increase in blood tacrolimus (FK506) levels during diarrhea in liver‐transplanted children
J. I. Berengue (2003)
Effect of interferons on P-glycoprotein-mediated rhodamine-123 efflux in cultured rat hepatocytes.
Yukiko Akazawa (2002)
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
C. Staatz (2004)
Effect of Naringin on the Pharmacokinetics of Nifedipine in Rabbits
Chong-Hak Na (2005)
Role of efflux pumps and metabolising enzymes in drug delivery
Suresh Katragadda (2005)
LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE
M. Fakhoury (2005)
Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
J. Soyinka (2010)
Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by d-α-Tocopheryl Poly(Ethylene Glycol 1000) Succinate
V. Wacher (2002)
Effect of Interleukin 6 on the Hepatic Metabolism of Itraconazole and Its Metabolite Hydroxyitraconazole Using Primary Human Hepatocytes
P. O. Gubbins (2003)
Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts.
W. Charman (2000)
A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism.
D. Cong (2000)
The H2 Receptor Antagonist Nizatidine is a P-Glycoprotein Substrate: Characterization of its Intestinal Epithelial Cell Efflux Transport
A. Dahan (2009)
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
S. Mouly (2005)See more